Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
durvalumab + rintatolimod
- Development stage
- Phase 2
- Lead developer
- AIM ImmunoTech
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Ampligen + Imfinzi is an investigational combination therapy consisting of rintatolimod (Ampligen), a synthetic double-stranded RNA (dsRNA) that acts as a highly selective Toll-like receptor 3 (TLR3) agonist, and durvalumab (Imfinzi), an anti-PD-L1 monoclonal antibody. Developed in collaboration by AIM ImmunoTech, AstraZeneca, and Erasmus Medical Center, this combination is designed to synergistically activate both the innate and adaptive arms of the immune system to overcome immune resistance in tumors. It is currently being evaluated in the investigator-initiated Phase 1b/2 DURIPANC trial (NCT05927142) as a maintenance therapy for patients with metastatic pancreatic ductal adenocarcinoma (PDAC) whose disease has stabilized following FOLFIRINOX chemotherapy.
- Other names
- Ampligen + Imfinzirintatolimod + durvalumab
02
Targets
FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)IFIH1 (MDA5)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)DDX58 (Retinoic acid-inducible gene I protein)TLR3 (Toll-like receptor 3)TRIF (TIR-domain-containing adapter-inducing interferon-beta)
Beyond the preview
Go deeper on durvalumab + rintatolimod.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on durvalumab + rintatolimod.